Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr:165:25-26.
doi: 10.1016/j.ejca.2022.01.010. Epub 2022 Feb 18.

Omicron variant: A clear and present danger for patients with cancer

J Barrière  1 , G Zalcman  2 , L Fignon  3 , N Peiffer-Smadja  4 , C Audigier-Valette  5 , M Carles  6
Affiliations

Omicron variant: A clear and present danger for patients with cancer

J Barrière et al. Eur J Cancer. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement Authors have nothing to disclose.

References

    1. Barrière J., Carles M., Audigier-Valette C., Re D., Zoubir A., Seitz-Polski B., et al. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position paper. Eur J Cancer. 2022;162:182–193. - PMC - PubMed
    1. Pulliam J.R.C., van Schalkwyk C., Govender N., von Gottberg A., Cohen C., Groome M.J., et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv. 2021 2021.11.11.21266068. - PMC - PubMed
    1. Planas D., Saunders N., Maes P., Guivel-Benhassine F., Planchais C., Buchrieser J., et al. 2021. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization.http://biorxiv.org/lookup/doi/10.1101/2021.12.14.472630 - DOI - PubMed
    1. Barrière J., Chamorey E., Adjtoutah Z., Castelnau O., Mahamat A., Marco S., et al. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. Ann Oncol Off J Eur Soc Med Oncol. 2021;32:1053–1055. - PMC - PubMed
    1. Gruell H., Vanshylla K., Tober-Lau P., Hillus D., Schommers P., Lehmann C., et al. 2021. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.http://medrxiv.org/lookup/doi/10.1101/2021.12.14.21267769 - DOI - PMC - PubMed